Literature DB >> 16386370

Positive immunoreactivity for vesicular monoamine transporter 2 in Lewy bodies and Lewy neurites in substantia nigra.

Shoji Yamamoto1, Jiro Fukae, Hideo Mori, Yoshikuni Mizuno, Nobutaka Hattori.   

Abstract

Vesicular monoamine transporter 2 (VMAT2) is responsible for packing dopamine into vesicles, and reduces the effects of neurotoxins by sequestering them into vesicles. In this report, we tested the hypothesis that VMAT2 is associated with Lewy body (LB) formation by immunohistochemical staining of midbrain and cortical sections of autopsied brains of patients with Parkinson's disease (PD) and diffuse Lewy body disease (DLBD) for VMAT2 using a polyclonal antibody against VMAT2. LBs in the substantia nigra (SN) of PD and DLBD were immunoreactive for VMAT2, especially in the peripheral zone. Previous electron microscopic studies also revealed the presence of numerous dense core vesicles around the LBs, suggesting that these vesicles are related to LB formation. Indeed, the presence of a few vesicle-linked proteins such as synaptophysin and chromogranin A in LBs has been reported. Together with the low expression of VMAT2 in the SN of PD, the involvement of VMAT2 in LBs of the SN suggests the association of this protein in the neurodegeneration of nigral neurons in PD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16386370     DOI: 10.1016/j.neulet.2005.11.068

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  10 in total

Review 1.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

2.  Experimenting with spirituality: analyzing The God Gene in a nonmajors laboratory course.

Authors:  Linda A Silveira
Journal:  CBE Life Sci Educ       Date:  2008       Impact factor: 3.325

Review 3.  Synuclein modulation of monoamine transporters.

Authors:  Adam W Oaks; Anita Sidhu
Journal:  FEBS Lett       Date:  2011-03-23       Impact factor: 4.124

4.  Expression Analysis of Genes Involved in Transport Processes in Mice with MPTP-Induced Model of Parkinson's Disease.

Authors:  Margarita M Rudenok; Maria I Shadrina; Elena V Filatova; Ivan N Rybolovlev; Maxim S Nesterov; Denis A Abaimov; Ruslan A Ageldinov; Anna A Kolacheva; Michael V Ugrumov; Petr A Slominsky; Anelya Kh Alieva
Journal:  Life (Basel)       Date:  2022-05-19

5.  VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease.

Authors:  Ming-Kai Chen; Hiroto Kuwabara; Yun Zhou; Robert J Adams; James R Brasić; Jennifer L McGlothan; Tatyana Verina; Neal C Burton; Mohab Alexander; Anil Kumar; Dean F Wong; Tomás R Guilarte
Journal:  J Neurochem       Date:  2007-11-05       Impact factor: 5.372

Review 6.  Alpha-synuclein modulates dopamine neurotransmission.

Authors:  Brittany Butler; Danielle Sambo; Habibeh Khoshbouei
Journal:  J Chem Neuroanat       Date:  2016-06-19       Impact factor: 3.052

7.  Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems.

Authors:  F S Hall; K Itokawa; A Schmitt; R Moessner; I Sora; K P Lesch; G R Uhl
Journal:  Neuropharmacology       Date:  2013-08-24       Impact factor: 5.250

Review 8.  Mechanisms of α-Synuclein Induced Synaptopathy in Parkinson's Disease.

Authors:  Jessika C Bridi; Frank Hirth
Journal:  Front Neurosci       Date:  2018-02-19       Impact factor: 4.677

Review 9.  Tau and Alpha Synuclein Synergistic Effect in Neurodegenerative Diseases: When the Periphery Is the Core.

Authors:  Elena Vacchi; Alain Kaelin-Lang; Giorgia Melli
Journal:  Int J Mol Sci       Date:  2020-07-16       Impact factor: 5.923

Review 10.  Living in Promiscuity: The Multiple Partners of Alpha-Synuclein at the Synapse in Physiology and Pathology.

Authors:  Francesca Longhena; Gaia Faustini; Maria Grazia Spillantini; Arianna Bellucci
Journal:  Int J Mol Sci       Date:  2019-01-02       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.